JPRN-jRCT2080223406未知3 期
A compassionate use study of R435(Bevacizumab) in chemotherapy naive and inoperable malignant pleural mesothelioma patients
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •ECOG Performance status 0 to 2
- •- Histologically confirmed malignant pleural mesothelioma which is inoperable
- •- Chemotherapy naive (including pre or post operative adjuvant chemotherapy)
- •- Identifiable tumor image present
排除标准
- •- History of anti-tumor therapy(chemotherapy, Immunotherapy or biotherapy)
- •- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abcess in the last 6 months
- •- Clinical symptoms accompanying or treatment requiring metastasis to central nervous system
- •- History of cerebral vascular accident or transient ischemic attack in the last 6 months
研究者
相似试验
未知
1 期
Phase I/II study of R435 (Bevacizumab) in patients with metastatic colorectal cancerMetastatic colorectal cancerJPRN-jRCT2080220022Chugai Pharmaceutical Co., Ltd.
未知
3 期
A study of R435 (Bevacizumab) in Combination With R340 (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.Gastric CancerJPRN-jRCT2080220416Chugai Pharmaceutical Co., Ltd.
未知
2 期
Phase II clinical study of R435 (bevacizumab) in combination with paclitaxel in patients with inoperable metastatic breast cancerInoperable metastatic breast cancerJPRN-jRCT2080220385Chugai Pharmaceutical Co., Ltd.
未知
3 期
Safety comformation study of R435 (Bevacizumab) in patients with metastatic colorectal cancerMetastatic colorectal cancerJPRN-jRCT2080220205Chugai Pharmaceutical Co., Ltd.
未知
2 期
A Phase II Trial of R435(Bevacizumab) in stage IVB, persistent or recurrent carcinoma of the cervixadvanced or recurrent carcinoma of the cervixJPRN-jRCT2080222700Chugai Pharmaceutical Co., Ltd.6